Capital Fund Management (CFM)
AXSM icon

Capital Fund Management (CFM)’s Axsome Therapeutics AXSM Stock Holding History

Capital Fund Management (CFM)’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,600
Closed -$762K – 1921
2023
Q2 		$762K Buy
+10,600
New +$782K ﹤0.01% 1484
2020
Q3 		– Sell
-11,400
Closed -$938K – 1190
2020
Q2 		$938K Buy
+11,400
New +$877K 0.01% 715

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Fund Management (CFM)'s AXSM Position: Q4 2025 in Review

Capital Fund Management (CFM) sold out of Axsome Therapeutics (AXSM) in Q4 2025, closing a stake of 28,758 shares — an estimated $3.49M sold.

Capital Fund Management (CFM) first reported a position in AXSM in Q1 2022 and held it in 6 quarters. The position peaked at $6.34M in Q2 2025. 398 funds tracked by Wall St. Rank hold AXSM as of Q4 2025.

  • Capital Fund Management (CFM) reported no remaining Axsome Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 28,758 Axsome Therapeutics shares in Q4 2025, an estimated $3.49M.
  • Capital Fund Management (CFM) first reported a position in Axsome Therapeutics in Q1 2022 and held it in 6 quarters.
  • Capital Fund Management (CFM)'s Axsome Therapeutics position peaked at $6.34M in Q2 2025.
  • 398 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q4 2025, filed 17 Feb 2026.